Preliminary findings from a phase I, multicenter, open-label study of the anti-CD37 antibody-drug conjugate (ADC), IMGN529, in adult patients with relapsed or refractory non-Hodgkin lymphoma (NHL).
Anastasios Stathis
No relevant relationships to disclose
Kami J. Maddocks
No relevant relationships to disclose
Ian Flinn
Research Funding - Immunogen
Alex Mejia
No relevant relationships to disclose
Maria Lia Palomba
No relevant relationships to disclose
Sybil Zildjian
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Mary Murphy
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Jutta Deckert
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Rodrigo Ruiz-Soto
Employment or Leadership Position - Immunogen
Stock Ownership - Immunogen
Arnold Freedman
No relevant relationships to disclose